The National Institute of Oncology in Gliwice has launched a pioneering clinical study using a novel radiotracer for immuno-PET imaging. As one of the first initiatives of its kind in the region, the project marks a meaningful step forward for advanced diagnostics in Central and Eastern Europe.
At Axcellant, we closely follow developments in the field of nuclear medicine and molecular imaging, particularly where they intersect with clinical research. Imaging-based trials, such as this one, are not only scientifically ambitious but also logistically complex. Successfully executing such studies requires a deep understanding of regulatory frameworks, robust imaging infrastructure, and tight coordination between interdisciplinary teams.
Poland’s growing activity in this space is an encouraging sign for sponsors looking for experienced research partners beyond traditional Western hubs. As a CRO with strong expertise in imaging-supported clinical trials, we welcome this progress and look forward to supporting more innovation in the region.
Read the full article (in Polish) here.
We’re pleased to announce a strategic partnership between Axcellant and Prometheus MedTech.AI — a medtech startup developing AI-powered solutions for…
The Axcellant team has returned from the European Association of Nuclear Medicine (EANM) Annual Congress in Barcelona — and it’s…
The robust development of nuclear medicine depends on the availability of radioactive isotopes, some of which are used for diagnostic…
Copyright @ 2026 Axcellant